Global health care company Fresenius Kabi USA has rolled out its Levofloxacin in 5% Dextrose injection in freeflex containers, designed for better infusion of solutions.
Considering easy handling with improved safety and environmental performance, the Freeflex container has been manufactured using multilayer polyolefin film, which is free from PVC, plasticizer and is non-DEHP.
Fresenius Kabi USA president and CEO John Ducker said, "The introduction of Levofloxacin using the freeflex technology expands our market leading anti-infective business with a ready to use formulation and provides customers with a new choice in serving their patients."
A fluoroquinolone antibacterial, Levofloxacin has been indicated for the healing of bacterial infections caused by susceptible bacteria, such as pneumonia, bronchitis, skin infections, urinary tract infections, prostatitis and anthrax.
In June 2013, the US FDA gave its approval for Fresenius Kabi's Levofloxacin in 5% Dextrose Injection.
